Skip to main content
Home

Main navigation

  • About pCPA
    • Who we are
    • Governance
    • Strategic plan
    • Reports
    • What's new
    • FAQs
    • Careers
  • Negotiations
    • Recent updates
    • Forms and publications
    • Brand name drugs
      • Negotiations status
      • Negotiation process
    • Generic drugs
    • Biologics/Biosimilars
    • pCPA Temporary Access Process (pTAP)
  • Contact us
  • EN
  • FR

Forms and publications

Strategy

  • pCPA Dashboard - February 2025
  • pCPA Strategic plan
  • pCPA Strategic revitalization summary

Brand name drugs

  • pCPA Brand process guidelines

Generic drugs

  • TPF/Market entry form
  • TPF/Market exit form
  • pan-Canadian price tier confirmation process flowchart
  • pan-Canadian price tier market exit eligibility flowchart
  • Generics tiered pricing framework FAQs
  • Historical products policy

Biologics/Biosimilars

  • First principles for subsequent entry biologics
  • Biologics policy directions & pCPA negotiations
  • Biologics policy directions & pCPA negotiations FAQs
  • Biosimilars review process & pCPA negotiations update
  • National online consultation on the use and implementation of biosimilars
  • National in-person consultation on the use and implementation of biosimilars
  • Manufacturer notification of intent to negotiate a biosimilar form
About pCPA
  • Who We Are
  • Governance
  • Strategic Plan
  • Reports
  • FAQs
  • Careers

footer pcpa logo

About us

Contact us

What's new

Careers

© 2025 pan-Canadian Pharmaceutical Alliance

Privacy Policy   Terms of Use